DONATE

Publications

Access IBEC scientific production portal (IBEC CRIS), for more detailed information and advanced search features.

Find here the list of all IBEC's publications by year.

by Keyword: Virulence factor

Liu, Jinxia, Garcia-Guevara, Fernando, Macnaughtan, Jane, Jin, Yi, Ferret-Minana, Ainhoa, Clasen, Frederick, Yuen, Nicholas, Maset, Ramon Garcia, Ramon-Azcon, Javier, Kerbert, Annarein J C, Portlock, Theo, Martinez, Javier, Habtesion, Abeba, Phillips, Alexandra, De Chiara, Francesco, Ingavle, Ganesh, Baldwin, Tom, Jimenez, Cesar, Zaccherini, Giacomo, Husi, Katherine, Rodriguez-Gandia, Miguel, Cordero-Sanchez, Paul, Soeda, Junpei, Oben, Jude A, Church, Karen, Li, Jia V, Jalan, Aarti, Juanola, Adria, Sola, Elsa, Eaton, Simon, Morgan, Carrie, Avery, Thomas, Kowalski, Michal, Green, Daniel, Gander, Amir, Edwards, Lindsey Ann, Cox, I Jane, Cortez-Pinto, Helena, Wiest, Reiner, Durand, Francois, Caraceni, Paolo, Elosua, Roberto, Vila, Joan, Pavesi, Marco, Arroyo, Vicente, Davies, Nathan, Mookerjee, Rajeshwar P, Sandeman, Susan, Mehta, Gautam, Marchesi, Julian R, Albillos, Agustin, Rohn, Jennifer L, Andreola, Fausto, Shoaie, Saeed, Jalan, Rajiv, (2026). Impact ofYAQ001on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis LIVER INTERNATIONAL 46, e70933

Background & Aims YAQ001 is a novel, non-absorbable, gut-restricted, multiporous, carbon bead adsorbent. Pre-clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with biomarkers of gut permeability and systemic inflammation.Methods Twenty-eight-patients with cirrhosis were randomized (double-blind) to receive YAQ001 (4 g once daily) or placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12 weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae biofilms was assessed in vitro.Results Overall alpha and beta diversity remained unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens, a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia, and Streptococcus mutans. YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures, and lipopolysaccharides that are associated with inflammation and invasion. Antibiotic resistance genes decreased significantly in the YAQ001 group. These changes were associated with a reduction in markers of gut permeability and systemic inflammation. YAQ001 prevented K. pneumoniae biofilms in vitro.Conclusion YAQ001 was associated with favourable compositional shifts and trends towards reduced virulence-related gene signatures in the gut microbiome, alongside trends towards improved inflammatory biomarkers. The in vitro anti-biofilm effect of YAQ001 warrants further mechanistic investigation. The findings position YAQ001 as a potential microbiome therapeutic.

JTD Keywords: Antimicrobial resistance, Biofilm, Liver, Liver cirrhosis, Virulence, Virulence factor, Yaq001


Mulet, Maria, Milan, Jose Antonio Sanchez, Lorca, Cristina, Fernandez-Rhodes, Maria, Adrados-Planell, Ana, Castillo, Maria Consuelo Bejarano, Saiz, Laura, Mateos-Moreno, Maria-Victoria, Hase, Yoshiki, Mira, Alex, Rabano, Alberto, del Ser, Teodoro, Kalaria, Raj N, Lagunas, Anna, Mir, Monica, Crespo, Andres, Samitier, Josep, Gallart-Palau, Xavier, Serra, Aida, (2025). Oral Microbiome-Derived Proteins in Brain Extracellular Vesicles Circulate and Tie to Specific Dysbiotic and Neuropathological Profiles in Age-Related Dementias MOLECULAR & CELLULAR PROTEOMICS 24, 101464

The involvement of the oral microbiome (OM) in the pathophysiology of Alzheimer's disease and vascular dementia has been recognized epidemiologically, but the molecular mechanisms remain elusive. In this study, we uncovered the presence of OM-derived proteins (OMdPs) in brain extracellular vesicles (bEVs) from post-mortem Alzheimer's disease and vascular dementia subjects using unbiased metaproteomics. OMdP circulation in blood EVs was also confirmed in an independent cohort. Our findings also reveal that specific OMdPs are present in bEVs, with their levels varying with disease progression. Peptidome-wide correlation analyses further explored their exchange dynamics and composition within bEVs. In addition, we validated the ability of OM-derived EVs to cross the blood-brain barrier using a blood-brain barrier-on-a-chip model, confirming a potential route for bacterial-derived molecules to reach the central nervous system. Bioinformatics-driven interaction analyses indicated that OMdPs engage with key neuropathological proteins, including amyloid-beta and tau, suggesting a novel mechanism linking dysbiotic OM to dementia. These results provide new insights into the role of the OM in neurodegeneration and highlight OMdPs as potential biomarkers and therapeutic targets.

JTD Keywords: Alzheimers-disease, Communication, Expression, Gut microbiota, Health, Insights, Rna, Virulence factors


Javier-Reyna, R, Avalos-Padilla, Y, Marion, S, (2023). Editorial: Vesicular transport, the actin cytoskeleton and their involvement in virulence mechanisms during host-parasite interaction Frontiers in Cellular and Infection Microbiology 13, 1229067